MX2016000650A - Un metodo para tratar la hemorragia, choque y lesion cerebral. - Google Patents

Un metodo para tratar la hemorragia, choque y lesion cerebral.

Info

Publication number
MX2016000650A
MX2016000650A MX2016000650A MX2016000650A MX2016000650A MX 2016000650 A MX2016000650 A MX 2016000650A MX 2016000650 A MX2016000650 A MX 2016000650A MX 2016000650 A MX2016000650 A MX 2016000650A MX 2016000650 A MX2016000650 A MX 2016000650A
Authority
MX
Mexico
Prior art keywords
shock
brain injury
subject
potassium channel
haemorrhage
Prior art date
Application number
MX2016000650A
Other languages
English (en)
Inventor
Dobson Geoffrey
Original Assignee
Hibernation Therapeutics A Kf Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2013902657A external-priority patent/AU2013902657A0/en
Application filed by Hibernation Therapeutics A Kf Llc filed Critical Hibernation Therapeutics A Kf Llc
Publication of MX2016000650A publication Critical patent/MX2016000650A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La invención se refiere a una composición y método para incrementar la presión sanguínea, que incluye un estado analgésico o con poco dolor o la anestesia hipotensiva en un sujeto que ha padecido un choque o una hipotensión potencialmente letales o para reducir la hipofusión en todo el cuerpo de un sujeto. La composición comprende (i) un compuesto seleccionado entre al menos uno de los siguientes: un agente para la apertura de los canales de potasio, un agonista de los canales de potasio y un agonista de los receptores de adenosina; y (ii) un agente antiarrítmico o un anestésico local.
MX2016000650A 2013-07-17 2014-07-17 Un metodo para tratar la hemorragia, choque y lesion cerebral. MX2016000650A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
AU2013902657A AU2013902657A0 (en) 2013-07-17 A method for reducing infection, sepsis and injury
AU2013902656A AU2013902656A0 (en) 2013-07-17 A method for inducing whole body arrest
AU2013902658A AU2013902658A0 (en) 2013-07-17 A method for reducing inflammation, coagulation and adhesions
AU2013902659A AU2013902659A0 (en) 2013-07-17 A method for treating haemorrhage, shock and brain injury
AU2013903644A AU2013903644A0 (en) 2013-09-23 A method for organ arrest, protection and preservation and reducing tissue injury
PCT/AU2014/050130 WO2015006828A1 (en) 2013-07-17 2014-07-17 A method for treating haemorrhage, shock and brain injury

Publications (1)

Publication Number Publication Date
MX2016000650A true MX2016000650A (es) 2016-11-30

Family

ID=52345629

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2016000649A MX2016000649A (es) 2013-07-17 2014-07-17 Un metodo para tratar la infeccion, sepsis y lesion.
MX2016000651A MX2016000651A (es) 2013-07-17 2014-07-17 Metodo para la parada, proteccion y conservacion de organos y reduccion de la lesion tisular.
MX2016000650A MX2016000650A (es) 2013-07-17 2014-07-17 Un metodo para tratar la hemorragia, choque y lesion cerebral.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2016000649A MX2016000649A (es) 2013-07-17 2014-07-17 Un metodo para tratar la infeccion, sepsis y lesion.
MX2016000651A MX2016000651A (es) 2013-07-17 2014-07-17 Metodo para la parada, proteccion y conservacion de organos y reduccion de la lesion tisular.

Country Status (8)

Country Link
US (3) US20160158280A1 (es)
EP (3) EP3021856B1 (es)
CN (3) CN105705151A (es)
AU (3) AU2014292826A1 (es)
BR (3) BR112016000809A2 (es)
CA (3) CA2917629A1 (es)
MX (3) MX2016000649A (es)
WO (5) WO2015006830A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011242697B2 (en) 2010-04-21 2015-01-22 Government Of The United States Fluoroscopy-independent, endovascular aortic occlusion system
US9474882B2 (en) 2013-02-26 2016-10-25 Prytime Medical Devices, Inc. Fluoroscopy-independent balloon guided occlusion catheter and methods
EP3043858B1 (en) 2013-09-09 2022-11-02 Prytime Medical Devices, Inc. Low-profile occlusion catheter
US10232142B2 (en) 2014-06-10 2019-03-19 Prytime Medical Devices, Inc. Conduit guiding tip
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US10149962B2 (en) 2015-03-19 2018-12-11 Prytime Medical Devices, Inc. System and method for low-profile occlusion balloon catheter
US10688153B2 (en) 2015-11-06 2020-06-23 The Board Of Trustees Of The University Of Illinois Peptides and method for treatment of cardiac arrest
WO2017137528A1 (en) * 2016-02-12 2017-08-17 Charité - Universitätsmedizin Berlin Adenosine a1 receptor agonist for use in treatment of status epilepticus
AU2017272335B2 (en) 2016-06-02 2018-06-14 Prytime Medical Devices, Inc. System and method for low profile occlusion balloon catheter
US10707531B1 (en) 2016-09-27 2020-07-07 New Dominion Enterprises Inc. All-inorganic solvents for electrolytes
CA3049539C (en) 2017-01-12 2022-09-20 The Regents Of The University Of California Endovascular perfusion augmentation for critical care
CN110769749B (zh) 2017-04-21 2023-05-09 加利福尼亚大学董事会 用于部分主动脉闭塞的主动脉流量计和泵
CA3066361A1 (en) 2017-06-07 2018-12-13 Shifamed Holdings, Llc Intravascular fluid movement devices, systems, and methods of use
EP3710076B1 (en) 2017-11-13 2023-12-27 Shifamed Holdings, LLC Intravascular fluid movement devices, systems, and methods of use
US20200330031A1 (en) * 2017-12-05 2020-10-22 Neurolndex Ltd. Systems and methods for anesthesia management
US10722631B2 (en) 2018-02-01 2020-07-28 Shifamed Holdings, Llc Intravascular blood pumps and methods of use and manufacture
CN108753683B (zh) * 2018-05-26 2022-02-15 温州医科大学 一种促进冻存组织器官和细胞活性复苏的溶液体系
WO2020047539A1 (en) * 2018-08-31 2020-03-05 Louisiana Tech Research Corporation System and method for network analysis of a patient's neuro-cardio-respiratory system
CN110352951A (zh) * 2018-11-15 2019-10-22 崔磊 一种无血清无dmso组织工程骨冻存液及其制备和冻存方法
CN109248173A (zh) * 2018-11-23 2019-01-22 浙江省人民医院 一种心脏停搏液
CN113795247B (zh) * 2018-12-14 2024-04-05 陈益祥 用于心脏手术的稳定心脏麻痹液
US20220152607A1 (en) * 2019-01-10 2022-05-19 Organ Assist B.V. An apparatus and a method for ex-vivo measurement of performance of a donor heart
EP3946379A4 (en) * 2019-03-29 2023-01-25 Virginia Commonwealth University POLYMER CARDIOPULMONARY RESUSCITATION AGENT
CN110057821B (zh) * 2019-04-16 2021-09-07 上海交通大学 用于人类配子快速冻融过程观测的低温显微成像系统
US20220317135A1 (en) * 2019-04-30 2022-10-06 University Of Florida Research Foundation, Inc. Biomarker panel for sepsis encephalopathy
JP2022540616A (ja) 2019-07-12 2022-09-16 シファメド・ホールディングス・エルエルシー 血管内血液ポンプならびに製造および使用の方法
US11654275B2 (en) 2019-07-22 2023-05-23 Shifamed Holdings, Llc Intravascular blood pumps with struts and methods of use and manufacture
US20220313144A1 (en) * 2019-09-12 2022-10-06 The General Hospital Corporation System amd method for determining treatment outcomes for neurological disorders based on functional connectivity parameters
EP4034218A4 (en) * 2019-09-24 2023-10-25 Penumbra, Inc. INFUSION CATHETER AND METHOD OF USE
US11724089B2 (en) 2019-09-25 2023-08-15 Shifamed Holdings, Llc Intravascular blood pump systems and methods of use and control thereof
CN110692580B (zh) * 2019-11-15 2021-11-02 苑春亭 一种刺参度夏池塘及安全通过夏眠的方法
CN113134116B (zh) * 2020-01-20 2022-09-06 山东威高宏瑞医学科技有限公司 内镜微创手术用的填充组合物及填充制剂
AU2021239935A1 (en) 2020-03-16 2022-10-06 Certus Critical Care, Inc. Blood flow control devices, systems, and methods and error detection thereof
CN111407244A (zh) * 2020-03-30 2020-07-14 上海大学 基于svr算法的左心室收缩末期弹性预测方法及系统
CN111345293B (zh) * 2020-04-08 2021-08-27 江门海关技术中心 一种虫类标本用防蛀剂及其制备方法
CN111937861B (zh) * 2020-08-17 2021-10-26 南昌大学第二附属医院 一种七氟烷缺血再灌注装置及使用方法
CN112195151B (zh) * 2020-10-28 2022-06-21 范德里希(上海)生物科技有限公司 一种牙髓间充质干细胞复苏培养液、制备方法及复苏培养方法
CN112826463B (zh) * 2020-12-31 2023-11-10 苏州爱琴生物医疗电子有限公司 一种血压调控范围的确定装置和相关设备
EP4307994A1 (en) * 2021-03-18 2024-01-24 Washington University Hemodilution detector
CN113854280B (zh) * 2021-09-06 2022-05-31 创芯国际生物科技(广州)有限公司 一种低温保存液及其制备方法和应用
WO2023154844A2 (en) * 2022-02-10 2023-08-17 Workman David Henry Compositions comprising nad+ and associated methods of treatment
WO2023245103A2 (en) * 2022-06-15 2023-12-21 Vascular Perfusion Solutions, Inc. Tissue perfusion and viability sensing system
WO2024050139A1 (en) * 2022-09-02 2024-03-07 AnaBios Corporation Therapeutic uses of cardiac myosin inhibitors

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3795581A (en) * 1971-11-01 1974-03-05 American Hospital Supply Corp Method of maintaining or restoring the 2,3-diphosphoglycerate content of human red cells
US4112070A (en) * 1977-06-08 1978-09-05 Research Corporation Blood preservation system
SU878297A1 (ru) 1978-05-03 1981-11-07 Научно-Исследовательский Институт Трансплантологии И Искусственных Органов Состав дл сохранени жизнеспособности оперируемого сердца
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
US5006512A (en) 1987-10-02 1991-04-09 Tsuyoshi Ohnishi Therapeutic usages of inhibitors for a potassium efflux channel
US4968675A (en) * 1988-10-28 1990-11-06 Upjohn Non-hemolytic lazaroid parenteral formulation
US5256770A (en) 1990-04-09 1993-10-26 Schering Ag Oxidation resistant thrombomodulin analogs
DE3926287A1 (de) 1989-08-09 1991-02-21 Bernhard Clasbrummel Medizinische anwendung von omega-conotoxin gvia oder omega-conotoxin gvia-analoga zur sympathikolyse
US5145771A (en) 1990-04-12 1992-09-08 The University Of North Carolina At Chapel Hill Rinse solution for organs and tissues
US5206222A (en) 1991-05-22 1993-04-27 Vanderbilt University Methods for the reduction of myocardial reperfusion injury
US5407793A (en) 1991-10-18 1995-04-18 University Of Pittsburgh Of The Commonwealth System Of Higher Education An aqueous heart preservation and cardioplegia solution
RU2025973C1 (ru) 1992-02-10 1995-01-09 Научно-производственное предприятие "Биофарм" Раствор для консервации живых органов
US5370989A (en) 1992-04-03 1994-12-06 The Trustees Of Columbia University In The City Of New York Solution for prolonged organ preservation
US5405742A (en) * 1993-07-16 1995-04-11 Cyromedical Sciences, Inc. Solutions for tissue preservation and bloodless surgery and methods using same
AU2690695A (en) * 1994-05-25 1995-12-18 Jerry I. Jacobson Method and apparatus for ameliorating aging process
US5679706A (en) 1994-09-30 1997-10-21 Bristol-Myers Squibb Company Combination of a potassium channel activator and an antiarrhythmic agent
US5554497A (en) 1994-12-12 1996-09-10 Charlotte-Mecklenburg Hospital Authority Cardioplegic solution for arresting an organ
US5656420A (en) 1995-02-24 1997-08-12 University Of Kentucky Research Foundation Method for employing the delta opioid dadle to extend tissue survival time during ischemia
WO1997016169A1 (en) * 1995-11-01 1997-05-09 Chiron Corporation Treatment of a cardiovascular indication by delivery of therapeutics to the pericardial space
JP3875295B2 (ja) 1995-11-30 2007-01-31 功 竹内 心筋保護液
US5939394A (en) * 1996-01-18 1999-08-17 Fleming & Company Methods and compositions for the prevention and treatment of immunological disorders, inflammatory diseases and infections
US6043224A (en) 1996-09-05 2000-03-28 The Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
IT1297886B1 (it) 1997-02-28 1999-12-20 Carmine Antropoli Nifedipina per uso topico
EP1014995A4 (en) 1997-06-18 2005-02-16 Aderis Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR PREVENTING RESTENOSES CONSECUTIVE TO REVASCULARIZATION INTERVENTIONS
CN1057192C (zh) 1997-09-10 2000-10-11 上海长征医院 一种配制多器官保存液的方法
US6011017A (en) 1998-04-15 2000-01-04 Cypros Pharmaceutical Corp. Method of reducing pulmonary hypertension and atrial fibrillation after surgery using cardiopulmonary bypass
CA2336902C (en) 1998-07-16 2009-04-21 Memorial Sloan-Kettering Cancer Center Topical compositions comprising an opioid analgesic and an nmda antagonist
WO2000024378A1 (en) 1998-10-23 2000-05-04 Polyheal Ltd Compositions of microspheres for wound healing
US6358208B1 (en) 1998-11-21 2002-03-19 Philipp Lang Assessment of cardiovascular performance using ultrasound methods and devices that interrogate interstitial fluid
EP1168912B1 (en) 1999-03-23 2007-05-09 Hibernation Therapeutics Limited Organ arrest, protection and preservation
US6586413B2 (en) 1999-11-05 2003-07-01 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
GB9930079D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
AU2001231189A1 (en) 2000-01-27 2001-08-07 Childrens Hospital Research Foundation Transdermal anesthetic and vasodilator composition and methods for topical administration
JP2001261575A (ja) 2000-03-13 2001-09-26 General Hospital Corp 血管収縮を調節する方法とその組成物
US6569615B1 (en) 2000-04-10 2003-05-27 The United States Of America As Represented By The Department Of Veteran's Affairs Composition and methods for tissue preservation
US6271228B1 (en) 2000-04-28 2001-08-07 Pfizer Inc. Blood pressure stabilization during hemodialysis
IL152473A0 (en) 2000-04-28 2003-05-29 Sloan Kettering Inst Cancer Topical anesthetic/opioid formulations and uses thereof
DE60121458T2 (de) 2000-09-26 2007-02-15 Medtronic, Inc., Minneapolis Medizinische vorrichtung zur blutstromsteuerung
WO2006069170A2 (en) 2004-12-22 2006-06-29 Emory University Therapeutic adjuncts to enhance the organ protective effects of postconditioning
CA2474316A1 (en) 2002-01-29 2003-08-07 Cognetix, Inc. Kappa-pviia-related conotoxins as organ protectants
CA2379211A1 (fr) 2002-03-28 2003-09-28 Institut De Cardiologie De Montreal Utilisation du bleu de methylene pour renverser la reaction hemodynamique exageree induite par la combinaison d'un derive nitre et du sildenafil ou d'une molecule de meme classe (inhibiteur de la phosphodiesterase)
DE60325572D1 (de) 2002-04-18 2009-02-12 Cv Therapeutics Inc Methode zur behandlung von herzrhythmusstörungen mit einem a1 adenosin agonist zusammen mit einem beta blocker
AUPS312602A0 (en) 2002-06-21 2002-07-18 James Cook University Organ arrest, protection, preservation and recovery
US20040229780A1 (en) 2002-09-20 2004-11-18 Olivera Baldomero M. KappaM-conopeptides as organ protectants
US6921633B2 (en) 2002-11-18 2005-07-26 Biolife Solutions Incorporated Methods and compositions for the preservation of cells, tissues or organs in the vitreous state
US20040167226A1 (en) 2002-12-16 2004-08-26 Serafini Tito A. Methods for the treatment of pain and traumatic injury using benzamides and compositions containing the same
CA2551169A1 (en) 2002-12-23 2004-07-08 Global Cardiac Solutions Pty Ltd Organ preconditioning, arrest, protection, preservation and recovery
GB2436255B (en) 2002-12-23 2007-11-28 Global Cardiac Solutions Pty L Organ preconditioning, arrest, protection, preservation and recovery
US6992075B2 (en) 2003-04-04 2006-01-31 Barr Laboratories, Inc. C(14) estrogenic compounds
CA2561452A1 (en) 2003-06-02 2004-12-16 Samaritan Pharmaceuticals, Inc. Neuroprotective benzoate and benzamide compounds
US7049309B2 (en) 2003-10-14 2006-05-23 Bristol-Myers Squibb Company 3-Thia-4-arylquinolin-2-one potassium channel modulators
WO2007030198A2 (en) 2005-07-11 2007-03-15 Human Biosystems Improved methods and solutions for storing donor organs
EP2079301B1 (en) * 2006-05-29 2017-03-15 Hibernation Therapeutics, a KF LLC Improved tissue maintenance
CN101500409A (zh) * 2006-05-29 2009-08-05 低温药理有限公司 改善的组织维持
US20130122108A1 (en) * 2006-06-06 2013-05-16 Robert G Matheny Compositions for Regenerating Defective or Absent Myocardium
AU2007278754B2 (en) * 2006-07-25 2014-11-13 Hibernation Therapeutics, A Kf Llc Trauma therapy
BRPI0720550A2 (pt) * 2006-10-06 2014-07-08 Newsouth Innovations Pty Ltd Formação de partículas
WO2008106724A1 (en) * 2007-03-02 2008-09-12 Hibernation Therapeutics Limited Transplants
CN100423638C (zh) 2007-03-22 2008-10-08 南京吉脉生物技术有限公司 一种器官保存液及其制备方法
JP2010534208A (ja) * 2007-07-25 2010-11-04 ハイバーネイション セラピューティクス リミテッド 改善された臓器の保護、保存および回復
CN101496512A (zh) * 2008-02-01 2009-08-05 扬子江药业集团上海海尼药业有限公司 一种器官保存液及其制备方法
US20090198145A1 (en) * 2008-02-06 2009-08-06 Chow Harrison Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep
WO2011075391A1 (en) 2009-12-15 2011-06-23 Schering Corporation Formulations of acadesine
CN102726366B (zh) 2011-04-07 2014-06-04 中国人民解放军第二军医大学 一种器官保存液及其配制方法

Also Published As

Publication number Publication date
WO2015006828A9 (en) 2015-03-12
CN105722516A (zh) 2016-06-29
CN105705151A (zh) 2016-06-22
WO2015006831A1 (en) 2015-01-22
US10786525B2 (en) 2020-09-29
AU2014292827A9 (en) 2016-03-10
WO2015006828A1 (en) 2015-01-22
WO2015006831A9 (en) 2015-03-26
CA2917653A1 (en) 2015-01-22
AU2014292826A1 (en) 2016-02-04
EP3021856B1 (en) 2020-10-07
BR112016000898A2 (pt) 2017-08-22
AU2014292827A1 (en) 2016-02-04
WO2015006830A9 (en) 2016-01-28
EP3021856A4 (en) 2017-03-29
AU2014292825A1 (en) 2016-02-04
CA2917645C (en) 2022-06-21
CN105579045A (zh) 2016-05-11
EP3021856A1 (en) 2016-05-25
CA2917645A1 (en) 2015-01-22
EP3021855A4 (en) 2017-03-29
CA2917629A1 (en) 2015-01-22
EP3021854A4 (en) 2017-03-29
WO2015006830A1 (en) 2015-01-22
MX2016000649A (es) 2016-11-30
US20160158280A1 (en) 2016-06-09
US20160271161A1 (en) 2016-09-22
EP3021855A1 (en) 2016-05-25
WO2015006829A1 (en) 2015-01-22
US20160166598A1 (en) 2016-06-16
BR112016000804A2 (pt) 2017-08-22
MX2016000651A (es) 2016-10-14
WO2015006827A1 (en) 2015-01-22
BR112016000809A2 (pt) 2017-08-22
EP3021854A1 (en) 2016-05-25

Similar Documents

Publication Publication Date Title
MX2016000650A (es) Un metodo para tratar la hemorragia, choque y lesion cerebral.
MX2021002406A (es) Composiciones farmaceuticas que comprenden un inhibidor de il-4r para usarse en el tratamiento de la esofagitis eosinofilica.
PH12015501656A1 (en) Anti-il-33 antibodies and use thereof
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
MX2016015181A (es) Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
PE20180260A1 (es) Metodos y kits para tratar la depresion
MX2016000364A (es) Metodos para tratar o prevenir afecciones oftalmologicas.
MX2016013280A (es) Composiciones topicas para el alivio del dolor, manufactura y uso.
MX2016013323A (es) Uso medico de compuestos de artemisinina y agonistas de gefirina.
MX2016004741A (es) Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
MX365321B (es) Métodos para el tratamiento de neutropenia mediante agonistas retinoides.
EP4137147A3 (en) Uses of abaloparatide in reducing fracture risk
MX2020011190A (es) Angiotensina ii sola o en combinacion para usarse en el tratamiento de hipotension.
BR112017006113A2 (pt) combinações sinérgicas de auristatina
AU2019284019A1 (en) Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
MX2016006603A (es) Compuestos piperidinicos con actividad multimodal contra el dolor.
MX2020002741A (es) Uso de gaboxadol en el tratamiento de narcolepsia.
MX343059B (es) Derivados de desmetil-estradiol sustituido en 6 como agonistas de er-beta selectivos.
BR112016012248A2 (pt) método de tratamento de nefropatia
MX2018012361A (es) Metodos de tratamiento con agonistas selectivos del receptor cb2.
MX2018005035A (es) Formulaciones de liberacion sostenida de anestesicos locales.
MX2018004296A (es) Combinacion de un agonista selectivo de il-2rbeta y un agonista il-15 de accion prolongada.
EA201690446A1 (ru) Лечение множественной миеломы
EA201592120A1 (ru) Состав на основе наночастиц, содержащий антагонист trpa1
MX365021B (es) Composicion para tratar o prevenir enfermedades ocasionadas por permeabilidad vascular, que contiene como ingrediente activo imatinib o una sal farmaceuticamente aceptable del mismo.